We further validated the efficacy of JPX-1244 treatment in T-PLL-like cell lines, generated by introduction of TCL1A into T-cell leukemia lines (HuT78TCL1A, JurkatTCL1A, HHTCL1A) and in SUP-T11 cells (carrying a t(14;14)). Here, TCL1A is linked to T-cell leukemia.